Therapeutic advances of miRNAs: A preclinical and clinical update.

Therapeutic advances of miRNAs: A preclinical and clinical update.
复制标题

miRNAs的治疗进展:临床前和临床更新。

DOI:
10.1016/j.jare.2020.08.012
复制
发表时间:
2021-03
影响因子:
10.7
通讯作者:
Lee SS
Lee SS
中科院分区:
综合性期刊2区
文献类型:
--
作者:
Chakraborty C;Sharma AR;Sharma G;Lee SS

文献摘要

参考文献

被引文献

相似文献

MiRNAs是一类小的内源性RNA,是近年来作为下一代药物进入商业化阶段的重要生物药物之一。已经讨论了关于miRNAs作为生物制药的当前情景的快照。在这项工作中,对使用miRNA的生物制药公司以及关于miRNA疗法的临床前/临床试验的现状进行了综述。最后,对miRNAs的吸收、分布、代谢和排泄(ADME)以及传递系统的最新进展进行了说明。
miRNAs, a class of small endogenous RNAs, are one of the essential biopharmaceuticals which are in commercial spans as next-generation medicine in recent times. A snapshot of the current scenario regarding the miRNAs as biopharmaceuticals have been discussed. In this work, biopharmaceutical companies working with miRNAs and the current status of preclinical/clinical trials about miRNA therapeutics have been reviewed. Finally, recent updates on the absorption, distribution, metabolism, and excretion (ADME), as well as a delivery system of miRNAs, have been illustrated.
DOI: 10.1016/j.omtn.2017.06.005
发表时间: 2017-09-15
期刊: Molecular therapy. Nucleic acids
影响因子: --
作者:
Chakraborty C;Sharma AR;Sharma G;Doss CGP;Lee SS
通讯作者: Lee SS
DOI: 10.18632/oncotarget.24309
发表时间: 2018-02-09
期刊: Oncotarget
影响因子: --
作者:
Chakraborty C;Sharma AR;Sharma G;Sarkar BK;Lee SS
通讯作者: Lee SS
DOI: 10.1165/rcmb.2010-0323oc
发表时间: 2011-08-01
影响因子: 6.4
作者:
Cushing, Leah;Kuang, Ping Ping;Lue, Jining
通讯作者: Lue, Jining
DOI: 10.1038/nm.1880
发表时间: 2008-11-01
期刊: NATURE MEDICINE
影响因子: 82.9
作者:
Bonci, Desiree;Coppola, Valeria;De Maria, Ruggero
通讯作者: De Maria, Ruggero
DOI: 10.1007/s10637-016-0407-y
发表时间: 2017-04
影响因子: 3.4
作者:
Beg MS;Brenner AJ;Sachdev J;Borad M;Kang YK;Stoudemire J;Smith S;Bader AG;Kim S;Hong DS
通讯作者: Hong DS